Sustained conservation of CD4+ T cells in multiprotein triple modality-immunized rhesus macaques after intrarectal challenge with Simian immunodeficiency virus

Viral Immunology

Volumn 19, Issue 3, 2006, Pages 448-457

  Stolte Leeb, Nicole ^a   Sauermann, Ulrike ^a   Norley, Stephen ^b   Fagrouch, Zahra ^c   Heeney, Jonathan ^c   Franz, Monika ^a   Hunsmann, Gerhard ^a   Stahl Hennig, Christiane ^a  

^a GERMAN PRIMATE CENTER   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNIZATION; MUCOSAL IMMUNITY; NONHUMAN; RHESUS MONKEY; SEMLIKI FOREST ALPHAVIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; VACCINIA VIRUS; VIRUS GENE; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS VECTOR;

ADMINISTRATION, RECTAL; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; GENETIC VECTORS; IMMUNIZATION; IMMUNIZATION, SECONDARY; MACACA MULATTA; SAIDS VACCINES; SEMLIKI FOREST VIRUS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA; VACCINIA VIRUS;

ANIMALIA; MACACA MULATTA; SEMLIKI FOREST VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33750965784     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.448     Document Type: Conference Paper

References (41)

1. Allen TM, Sidney J, del Guercio MF, Glickman RL, Lensmeyer GL, Wiebe DA, DeMars R, Pauza C, Johnson RP, Sette A, and Watkins DI: Characterization of the peptide binding motif of a rhesus MHC class I molecule (MamuA*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J. Immunol. 1998;160:6062-6070.
2. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, and Robinson HL: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
3. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, S I. Staprans, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, McClure HM, McNicholl JM, B. Moss, and Robinson HL: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 2002;20:1949-1955.
4. Amara RR, Smith JM, Staprans SI, Montefiori DC, Villinger F, Altman JD, O'Neil SP, Kozyr NL, Xu Y, Wyatt LS, Earl PL, Herndon JG, McNicholl JM, McClure HM, Moss B, and Robinson HL: Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 2002;76:6138-6146.
5. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, and Ruprecht RM: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995;267:1820-1825.
6. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson R, Greene MF, McClure HM, Martin LN, and Ruprecht RM: Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 1999;5:194-203.
7. Barouch DH, and Letvin NL: DNA vaccination for HIV-1 and SIV. Intervirology 2000;43:282-287.
8. Berglund P, Smerdou C, Fleeton MN, Tubulekas I, and Liljestrom P: Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 1998;16:562-565.
9. Bertley FM, Kozlowski PA, S.W. Wang, Chappelle J, Patel J, Sonuyi O, Mazzara G, Montefiori D, Carville A, Mansfield KG, and Aldovini A: Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J. Immunol. 2004;172:3745-3757.
10. Cohen J: AIDS vaccines. HIV dodges one-two punch. Science 2004;305:1545-1547.
11. Egan MA, Charini WA, Kuroda MJ, Schmitz JE, Racz P, Tenner-Racz K, Manson K, Wyand M, Lifton MA, C.E. Nickerson, Fu T, Shiver JW, and Letvin NL: Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J. Virol. 2000;74:7485-7495.
12. Girard M, Habel A, and Chanel C: New prospects for the development of a vaccine against human immunodeficiency virus type 1: An overview. C. R. Acad. Sci. III 1999;322:959-966.
13. Greenough TC, Sullivan JL, and Desrosiers RC: Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N. Engl. J. Med. 1999;340:236-237.
14. Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM, Boyson JE, Sharpe SA, Cook N, Smith GL, Watkins DI, Cranage MP, and McMichael AJ: Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 1999;73:7524-7532.
15. Hanke T, McMichael AJ, Samuel RV, Powell LA, McLoughlin L, Crome SJ, and Edlin A: Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 2002;21:108-114.
16. Heeney JL, Koopman G, Rosenwirth B, Bogers W, van Dijk J, Nieuwenhuis I, Niphuis H, Ten Haaft P, Hanke T, Rhodes G, Berglund P, Burny A, Bex F, Sutter G, and Liljestrom P: A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens. J. Med. Primatol. 2000;29:268-273.
17. + T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization wilh three unrelated vaccine vectors encoding multiple SIV antigens. J. Gen. Virol. 2004;85:2915-2924.
18. Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, and Sullivan JS: Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1: A report from the Sydney Blood Bank Cohort. N. Engl. J. Med. 1999;340:1715-1722.
19. Lehner T, Wang Y, Ping L, Bergmeier L, Mitcheil E, Cranage M, Hall G, Dennis M, Cook N, Doyle C, and Jones I: The effect of route of immunization on mucosal immunity and protection. J. Infect. Dis. 1999;179(Suppl. 3):S489-S492.
20. Letvin NL, Barouch DH, and Montefiori DC: Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 2002;20:73-99.
21. Makitalo B, Lundholm P, Hinkula J, Nilsson C, Karlen K, Morner A, Sutter G, Erfle V, Heeney JL, Wahren B, Biberfeld G, and Thorstensson R: Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J. Gen. Virol. 2004;85:2407-2419.
22. Mayr A, Hochstein-Mintzel V, and Stickl H: Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 1975;3:6-14.
23. + lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 1997;126:946-954.
24. Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, and Sutter G: Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. 1996;397:7-13.
25. Muhl T, Krawczak M, Ten Haaft P, Hunsmann G, and Sauermann U: MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys. J. Immunol. 2002;169:3438-3446.
26. mac251 challenge in rhesus macaques. Vaccine 2003;21:629-637.
27. Negri DR, Baroncelli S, Catone S, Comini A, Michelini Z, Maggiorella MT, Sernicola L, Crostarosa F, Belli R, Mancini MG, Farcomeni S, Fagrouch Z, Ciccozzi M, Boros S, Liljestrom P, Norley S, Heeney J, and Titti F: Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. J. Gen. Virol. 2004;85:1191-1201.
28. Nilsson C, Makitalo B, Thorstensson R, Norley S, Binninger-Schinzel D, Cranage M, Rud E, Biberfeld G, and Putkonen P: Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 1998;12:2261-2270.
29. Nilsson C, Makitalo B, Berglund P, Bex F, Liljestrom P, Sutter G, Erfle V, Ten Haaft P, Heeney J, Biberfeld G, and Thorstensson R: Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 2001;19:3526-3536.
30. Ourmanov I, Brown CR, Moss B, Carroll M, Wyatt L, Pletneva L, Goldstein S, Venzon D, and Hirsch VM: Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 2000;74:2740-2751.
31. Piot P: The science of AIDS: A tale of two worlds. Science 1998;280:1844-1845.
32. Rhodes DI, Ashton L, Solomon A, Carr A, Cooper D, Kaldor J, and Deacon N: Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group. J. Virol. 2000;74:10581-10588.
33. Sauermann U, Stahl-Hennig C, Stolte N, Muhl T, Krawczak M, Spring M, Fuchs D, Kaup FJ, Hunsmann G, and Sopper S: Homozygosity for a conserved MHC class II DQ-DRB haplotype is associated with rapid disease progression in simian immunodeficiency virus-infected macaques: Results from a prospective study. J. Infect. Dis. 2000;182:716-724.
34. Seth A, Ourmanov I, Schmitz JE, Kuroda MJ, Lifton MA, Nickerson CE, Wyatt L, Carroll M, Moss B, Venzon D, Letvin NL, and Hirsch VM: Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. 2000;74:2502-2509.
35. Sharpe S, Polyanskaya N, Dennis M, Sutter G, Hanke T, Erfle V, Hirsch V, and Cranage M: Induction of simian immunodeficiency virus (SrV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: Influence of pre-existing anti-vector immunity. J. Gen. Virol. 2001;82:2215-2223.
36. + lymphocyte apoptosis in acutely SIV-infected rhesus macaques after short-term antiretroviral treatment. Virology 2001;279:221-232.
37. Stahl-Hennig C, Voss G, Nick S, Petry H, Fuchs D, Wachter H, Coulibaly C, Luke W, and Hunsmann G: Immunization with Tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection. Virology 1992;186:588-596.
38. Stahl-Hennig C, Dittmer U, Nisslein T, Petry H, Jurkiewicz E, Fuchs D, Wachter H, Matz-Rensing K, Kuhn EM, Kaup FJ, Rud EW, and Hunsmann G: Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J. Gen. Virol. 1996;77:2969-2981.
39. Ten Haaft P, Verstrepen B, Uberla K, Rosenwirth B, and Heeney J: A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J. Virol. 1998;72:10281-10285.
40. Tubulekas I, Berglund P, Fleeton M, and Liljestrom P: Alphavirus expression vectors and their use as recombinant vaccines: A minireview. Gene 1997;190:191-195.
41. Xiang QC, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, and Ertl HC: Oral vaccination of mice with is not impaired by preexisting immunity to the vaccine carrier. J. Virol. 2003;77:10780-10789.